{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:19:23Z","timestamp":1792718363327,"version":"4.5.0"},"reference-count":35,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Ivarmacitinib, a selective oral Janus kinase 1 (JAK1) inhibitor, has demonstrated efficacy for treating adults with moderate to severe atopic dermatitis (AD) in a phase 2 trial.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To evaluate the efficacy and adverse events of ivarmacitinib in adolescents and adults with moderate to severe AD.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This multicenter, double-blind, placebo-controlled phase 3 randomized clinical trial included patients aged 12 to 75 years with moderate to severe AD. Patients were enrolled from 53 sites in Canada and China from April 2021 to April 2022. Data were analyzed from July 11 to September 27, 2023.<\/jats:p><\/jats:sec><jats:sec><jats:title>Interventions<\/jats:title><jats:p>Patients were randomized (1:1:1) to receive once-daily 4- or 8-mg ivarmacitinib or placebo for 16 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Co-primary end points were the proportions of patients achieving an Investigator Global Assessment (IGA) score of 0 (clear) or 1 (almost clear) with at least a 2-grade improvement from baseline and an Eczema Area and Severity Index score improvement of 75% (EASI-75) at week 16.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Of 336 randomized patients (mean [SD] age, 31.1 [15.4] years; 213 [63.4%] male; 286 [85.1%] Asian), 113 received 4-mg ivarmacitinib, 112 received 8-mg ivarmacitinib, and 111 received placebo. At week 16, significantly more patients in the 4-mg ivarmacitinib group (41 of 113 [36.3%]; 95% CI, 27.5%-45.9%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) and the 8-mg ivarmacitinib group (47 of 112 [42.0%]; 95% CI, 32.7%-51.7%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) achieved an IGA score of 0 or 1 with at least a 2-grade improvement compared to the placebo group (10 of 111 [9.0%]; 95% CI, 4.4%-15.9%). EASI-75 responses were also significantly higher in the ivarmacitinib groups: 61 patients (54.0%; 95% CI, 44.4%-63.4%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) in the 4-mg group, and 74 (66.1%; 95% CI, 56.5%-74.8%; <jats:italic>P<\/jats:italic>\u2009&amp;amp;lt;\u2009.001) in 8-mg group compared to 24 patients (21.6%; 95% CI, 14.4%-30.4%) in the placebo group. Treatment-emergent adverse events were reported by 78 patients (69.0%) in the 4-mg group, 74 (66.1%) in the 8-mg group, and 72 (64.9%) in the placebo group. Serious treatment-emergent adverse events occurred in 3 patients (2.7%) in the 4-mg group, 2 (1.8%) in the 8-mg group, and 3 (2.7%) in the placebo group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This phase 3 randomized clinical trial determined that once-daily ivarmacitinib demonstrated significant efficacy and a favorable risk-benefit profile for treating moderate to severe AD in adults and adolescents. These results support the potential of ivarmacitinib as a new therapeutic option.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifier: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT04875169\">NCT04875169<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2025.0982","type":"journal-article","created":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T19:15:12Z","timestamp":1746040512000},"page":"688","source":"Crossref","is-referenced-by-count":27,"title":["Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and Adolescents"],"prefix":"10.1001","volume":"161","author":[{"given":"Yan","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Dermatology, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Gooderham","sequence":"additional","affiliation":[{"name":"Department of Dermatology, SKiN Centre for Dermatology, Peterborough, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Dermatology Hospital of Southern Medical University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyuan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Wuhan No. 1 Hospital, Wuhan, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, The First People\u2019s Hospital of Hangzhou, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Jing","family":"Loo","sequence":"additional","affiliation":[{"name":"DermEffects, London, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darryl","family":"Toth","sequence":"additional","affiliation":[{"name":"Department of Dermatology, XLR8 Medical Research, Windsor, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Sauder","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Toronto Research Centre, Waterloo, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Venereology, West China Hospital of Sichuan University, Chengdu, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Dermatology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohua","family":"Tao","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Zhejiang Province People\u2019s Hospital, Hangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyun","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Third Xiangya Hospital of Central South University, Changsha, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The Southwest Hospital of the Army Medical University, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiande","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Guangdong Province Traditional Chinese Medical Hospital, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yijing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Biometrics, Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Xu","sequence":"additional","affiliation":[{"name":"Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianzhong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Peking University People\u2019s Hospital, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"doi250014r1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.jaad.2018.09.025","article-title":"Association between atopic dermatitis and autoimmune disorders in US adults and children: a cross-sectional study.","volume":"80","author":"Narla","year":"2019","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"doi250014r2","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis.","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"doi250014r3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-018-0001-z","article-title":"Atopic dermatitis.","volume":"4","author":"Weidinger","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"doi250014r4","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1111\/jdv.19723","article-title":"Atopic dermatitis: A global health perspective.","volume":"38","author":"Faye","year":"2024","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"doi250014r5","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic Dermatitis in America Study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population.","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"issue":"3","key":"doi250014r6","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.anai.2018.07.006","article-title":"Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study.","volume":"121","author":"Silverberg","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"11","key":"doi250014r7","doi-asserted-by":"publisher","first-page":"587","DOI":"10.5694\/mja2.51560","article-title":"Management of atopic dermatitis: a narrative review.","volume":"216","author":"Goh","year":"2022","journal-title":"Med J Aust"},{"issue":"4","key":"doi250014r8","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s40257-019-00436-8","article-title":"Management recommendations for dupilumab partial and non-durable responders in atopic dermatitis.","volume":"20","author":"Hendricks","year":"2019","journal-title":"Am J Clin Dermatol"},{"issue":"24","key":"doi250014r9","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis.","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"doi250014r10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1068260","article-title":"JAK-STAT signaling pathway in the pathogenesis of atopic dermatitis: an updated review.","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"issue":"6","key":"doi250014r11","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1007\/s40257-020-00548-6","article-title":"Selective JAK1 inhibitors for the treatment of atopic dermatitis: focus on upadacitinib and abrocitinib.","volume":"21","author":"Ferreira","year":"2020","journal-title":"Am J Clin Dermatol"},{"issue":"11","key":"doi250014r12","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/nrd.2017.204","article-title":"Neuroimmunological disorders: JAK in the itch.","volume":"16","author":"Bordon","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"doi250014r13","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.3389\/fimmu.2019.02847","article-title":"Emerging topical and systemic JAK inhibitors in dermatology.","volume":"10","author":"Solimani","year":"2019","journal-title":"Front Immunol"},{"issue":"15","key":"doi250014r14","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.3390\/jcm11154431","article-title":"The JAK\/STAT pathway and its selective inhibition in the treatment of atopic dermatitis: a systematic review.","volume":"11","author":"Tsiogka","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"doi250014r15","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis.","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"doi250014r16","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamadermatol.2020.3260","article-title":"Efficacy and safety of baricitinib combined with topical corticosteroids for treatment of moderate to severe atopic dermatitis: a randomized clinical trial.","volume":"156","author":"Reich","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"10290","key":"doi250014r17","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1016\/S0140-6736(21)00588-2","article-title":"Once-daily upadacitinib versus placebo in adolescents and adults with moderate to severe atopic dermatitis (measure up 1 and measure up 2): results from two replicate double-blind, randomised controlled phase 3 trials.","volume":"397","author":"Guttman-Yassky","year":"2021","journal-title":"Lancet"},{"issue":"10246","key":"doi250014r18","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(20)30732-7","article-title":"Efficacy and safety of abrocitinib in adults and adolescents with moderate to severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial.","volume":"396","author":"Simpson","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"doi250014r19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20140712","article-title":"The molecular regulation of Janus Kinase (JAK) activation.","volume":"462","author":"Babon","year":"2014","journal-title":"Biochem J"},{"issue":"6","key":"doi250014r20","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s40257-021-00627-2","article-title":"Efficacy and safety of SHR0302, a highly selective Janus Kinase 1 Inhibitor, in patients with moderate to severe atopic dermatitis: a phase II randomized clinical trial.","volume":"22","author":"Zhao","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"doi250014r21","doi-asserted-by":"publisher","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis.","volume":"59","author":"Hanifin","year":"1980","journal-title":"Acta Derm Venereol Suppl (Stockh)"},{"issue":"12","key":"doi250014r22","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1001\/archderm.140.12.1513","article-title":"The patient-oriented eczema measure: development and initial validation of a new tool for measuring atopic eczema severity from the patients\u2019 perspective.","volume":"140","author":"Charman","year":"2004","journal-title":"Arch Dermatol"},{"issue":"3","key":"doi250014r23","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2013a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"6","key":"doi250014r24","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1111\/j.1365-2133.1995.tb16953.x","article-title":"The Children\u2019s Dermatology Life Quality Index (CDLQI): initial validation and practical use.","volume":"132","author":"Lewis-Jones","year":"1995","journal-title":"Br J Dermatol"},{"issue":"8","key":"doi250014r25","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","article-title":"Efficacy and safety of abrocitinib in patients with moderate to severe atopic dermatitis: a randomized clinical trial.","volume":"156","author":"Silverberg","year":"2020","journal-title":"JAMA Dermatol"},{"issue":"5","key":"doi250014r26","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1111\/bjd.19614","article-title":"Patient-oriented outcomes for atopic dermatitis.","volume":"184","author":"Vazquez","year":"2021","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi250014r27","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1111\/bjd.19457","article-title":"What are the best endpoints for Eczema Area and Severity Index and Scoring Atopic Dermatitis in clinical practice? A prospective observational study.","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br J Dermatol"},{"issue":"1","key":"doi250014r28","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jaip.2019.06.044","article-title":"Update on atopic dermatitis: diagnosis, severity assessment, and treatment selection.","volume":"8","author":"Fishbein","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"doi250014r29","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.jaci.2016.02.020","article-title":"The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves.","volume":"138","author":"Feld","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"doi250014r30","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.cell.2017.08.006","article-title":"Sensory neurons co-opt classical immune signaling pathways to mediate chronic itch.","volume":"171","author":"Oetjen","year":"2017","journal-title":"Cell"},{"issue":"6","key":"doi250014r31","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1053\/j.gastro.2022.08.007","article-title":"Efficacy and safety of ivarmacitinib in patients with moderate to severe, active, ulcerative colitis: a phase ii study.","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"issue":"5","key":"doi250014r32","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1016\/j.jaad.2023.02.063","article-title":"A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate to severe alopecia areata.","volume":"89","author":"Zhou","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"doi250014r34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1111\/exd.13514","article-title":"Atopic dermatitis in diverse racial and ethnic groups-Variations in epidemiology, genetics, clinical presentation and treatment.","volume":"27","author":"Kaufman","year":"2018","journal-title":"Exp Dermatol"},{"issue":"5","key":"doi250014r35","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/j.anai.2018.11.015","article-title":"Racial differences in atopic dermatitis.","volume":"122","author":"Brunner","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"doi250014r33","unstructured":"Zeng? XJY, Yang? Y, Li? HA. Multicenter, Randomized, Placebo-controlled, Double-blind Phase 2 Study of SHR0302 versus Placebo in Chinese Subjects with Moderate to Severe Active Rheumatoid Arthritis [abstract]. Arthritis Rheumatology. 2020. Accessed January 25, 2024. https:\/\/acrabstracts.org\/abstract\/a-multicenter-randomized-placebo-controlled-double-blind-phase-2-study-of-shr0302-versus-placebo-in-chinese-subjects-with-moderate to severe-active-rheumatoid-arthritis-ra\/"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2833318\/jamadermatology_zhao_2025_oi_250014_1752181143.74904.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T15:00:42Z","timestamp":1752678042000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2833318"}},"subtitle":["A Phase 3 Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":35,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2025.0982","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}